ArticleMolecular and clinical oncology2026
Cumulative cytotoxic chemotherapy exposure after the introduction of PARP inhibitors in advanced high-grade serous tubo-ovarian and primary peritoneal carcinoma: A descriptive single-center historical cohort study.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to describe real-world treatment patterns, cumulative exposure to cytotoxic chemotherapy, and exploratory survival outcomes before and after the clinical introduction of poly(ADP-ribose) polymerase (PARP) inhibitors in patients with stage III-IV high-grade serous ovarian, fallopian tube or primary peritoneal carcinoma. The medical records of patients with stage III-IV high-grade serous ovarian, fallopian tube or primary peritoneal carcinoma who received chemotherapy at Jichi Medical University Saitama Medical Center (Saitama, Japan) between January 2009 and August 2023 were retrospectively reviewed. The primary outcomes were the number of chemotherapy regimens and the cumulative number of cytotoxic chemotherapy cycles. Overall survival was evaluated as an exploratory secondary outcome. The final cohort included 86 patients, comprising 48 patients in the PARP inhibitor-untreated group and 38 patients in the PARP inhibitor-treated group. The groups exhibited differences in several baseline characteristics, including International Federation of Gynecology and Obstetrics stage, receipt of neoadjuvant chemotherapy and cytoreduction status. The cumulative number of cytotoxic chemotherapy cycles was significantly higher in the PARP inhibitor-untreated group than in the PARP inhibitor-treated group [median, 18.5 (range, 6-49) vs. 12.0 (range, 5-45); P=0.020], whereas the number of chemotherapy regimens did not differ significantly [median, 3 (range, 1-7) vs. 2 (range, 1-8); P=0.081]. Overall survival appeared to be longer in the PARP inhibitor-treated group; however, this finding should be interpreted with caution due to the retrospective historical design and baseline imbalances. In this descriptive single-center cohort restricted to advanced high-grade serous ovarian, fallopian tube or primary peritoneal carcinoma, the clinical introduction of PARP inhibitors was associated with lower cumulative exposure to cytotoxic chemotherapy. No causal inference regarding survival benefits could be made due to substantial treatment-selection bias and baseline imbalances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.